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ABSTRACT
Pulmonary embolism (PE) is diagnosed with increasing fre-
quency nowadays due to advances in the diagnostic methods
and the increased awareness of the disease. There is a tenden-
cy to use non invasive diagnostic methods for all diseases. 
D-dimer is a fibrin degradation product. We aimed to detect
the relationship between disease severity and the D-dimer
levels measured with two different methods. We compared
D-dimer levels in cases of massive vs. non-massive PE. A total
of 89 patients who were diagnosed between 2006 and 2008
were included in the study. Group 1 included patients whose
D-dimer levels were measured with the immunoturbidimetric
polyclonal antibody method (D-dimerPLUS®), while Group 2
patients made use of the immunoturbidimetric monoclonal
antibody method (InnovanceD-DIMER®). In each group, the 
D-dimer levels of those with massive and non-massive PE
were compared, using the Mann Whitney U test. The mean
age of Group 1 (25F/26M) was 56.0 ± 17.9 years, and that of
Group 2 (22F/16M) was 52.9 ± 17.9 years. There was no sta-
tistical difference in gender and mean age between the two
groups (p > 0.05). In Group 1, the mean D-dimer level of mas-
sive cases (n = 7) was 1444.9 ± 657.9 μg/L and that of non-
massive PE (n = 34) was 1304.7 ± 350.5 μg/L (p > 0.05). In
Group 2, the mean D-dimer level of massive cases (n = 6) was
9.7 ± 2.2 mg/L and that of non-massive PE (n = 32) was 5.9 ±
1.3 mg/L (p < 0.05). The mean D-dimer levels of massive cases
as measured with the immunoturbidimetric monoclonal anti-
body method were significantly higher. Pulmonary embolism
patients whose D-dimer levels are higher (especially higher
than 6.6 mg/L) should be considered as possibly having mas-
sive embolism. Diagnostic procedures and management can
be planned according to this finding.
Keywords: D-dimer, massive pulmonary embolism, pulmonary
embolism.
RIASSUNTO 
La diagnosi di embolia polmonare (EP) viene posta oggi giorno
con sempre maggiore frequenza grazie ai passi avanti della
metodologia diagnostica e alla maggiore consapevolezza di
malattia. In tutte le patologie si tende a ricorrere a metodi
non invasivi per giungere alla diagnosi. Il D-dimero è un pro-
dotto di degradazione della fibrina. Scopo di questo studio è
valutare il rapporto tra gravità di malattia e livelli di D-dimero
misurati con due metodiche differenti. Abbiamo comparato i
livelli D-dimero in casi di EP massiva e in casi non gravi di EP.
Sono stati selezionati 89 pazienti in cui è stata posta diagnosi
di EP tra il 2006 e il 2008. Al Gruppo 1 sono stati allocati i pa-
zienti ai quali il D-dimero era stato misurato mediante un 
metodo immunoturbidimetrico con anticorpi policlonali 
(D-dimer PLUS®), al Gruppo 2 i pazienti valutati mediante
metodo immunoturbidimetrico con anticorpi monoclonali
(InnovanceD-DIMER®). La comparazione tra i due gruppi è sta-
ta effettuata con il Mann Whitney U test. L’età media del
gruppo 1 (25F/26M) era 56,0 ± 17,9 anni, nel Gruppo 2
(22F/16M) era 52,9 ± 17,9 anni. Non vi era una differenza sta-
tisticamente significativa tra i due gruppi per sesso o età (p >
0,05). Nei pazienti più gravi del gruppo 1 (n = 7) il livello me-
dio di D-dimero era 1444,9 ± 657,9 μg/L, nei non gravi (n =
34) era 1304,7 ± 350,5 μg/L (p > 0,05). Nel gruppo 2 il livello
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medio di D-dimero nei gravi (n = 6) era 9,7 ± 2,2 mg/L e nei
non-gravi (n = 32) era 5,9 ± 1,3 mg/L (p < 0,05). Il livello me-
dio di D-dimero nei casi gravi in cui è stata utilizzata la meto-
dica con anticorpo monoclonale è risultato significativamen-
te più elevato rispetto ai pazienti meno gravi. Nei pazienti con
embolia polmonare il cui D-dimero è più elevato (specie se
superiore a 6,6 mg/L con la metodica ad anticorpi monoclo-
nali) dovrebbe essere considerata la possibilità di una embolia
massiva. I protocolli diagnostici e di gestione dei pazienti po-
trebbero perciò essere riformulati sulla base di questi risulta-
ti. 
Parole chiave: D-dimero, embolia polmonare, embolia polmo-
nare grave.
INTRODUCTION
Pulmonary embolism (PE) is diagnosed with in-
creasing frequency nowdays due to advances in the
diagnostic methods and the increased awareness of
the disease. There is a tendency to use non invasive
diagnostic methods for all diseases. Clinical out-
come studies have demonstrated that by using algo-
rithms with sequential diagnostic tests, PE can be
safely ruled out in patients whose clinical probabil-
ity indicates PE to be unlikely and whose D-dimer
test results are normal. 
The blood concentrations of D-dimer, which is a
degradation product of cross-linked fibrin, can be
elevated in acute venous thromboembolic disor-
ders. Different D-dimer assays have been intro-
duced for rapid and easy emergency testing. These
assays have either intermediate sensitivity and
specificity (manual whole-blood agglutination {sen-
sitivity 64-96%, specificity 48-84%}, qualitative la-
tex agglutination assays {sensitivity 25-96%, speci-
ficity 92-100%} and semi-quantitative latex aggluti-
nation assays {sensitivity 66-97%, specificity 43-
83%}) or high sensitivity at the cost of low specifici-
ty (ELISA {sensitivity 84-99%, specificity 29-71%}
and quantitative latex agglutination assays {sensitiv-
ity 88-98%, specificity 36-64%}). Higher sensitivity
results in a higher negative predictive value and
thus less concern about false negative test results,
while lower specificity yields less clinical utility as
the fraction of patients with normal test results will
decrease. 
We aimed to detect the relationship between dis-
ease severity in PE and the D-dimer levels measured
with two different methods.
MATERIALS AND METHODS
Patients 
Consecutive inpatients with PE were evaluated at
the pulmonology department of a university teach-
ing hospital. The exclusion criteria were: refusal or
inability to consent to the study and being on ther-
apeutic or prophylactic anticoagulant therapy at
time of presentation. Other causes of exclusion re-
garding the samples were insufficient sample vol-
ume and poor sample conditions (e.g. hemolyzed
or partially clotted). The study was conducted in ac-
cordance with the Declaration of Helsinki and good
clinical practice guidelines. The study protocol, pa-
tient information form and informed consent form
were approved by the local ethics committee. All
patients provided written informed consent before
beginning the study. 
A total of 89 patients who were diagnosed between
2006 and 2008 were included in the study. The pa-
tients who had right ventricular (RV) dysfunction on
echocardiography and hemodynamic instability
were considered as massive PE. Echocardiographic
findings of PE-induced RV pressure overload in-
clude the following: RV dilatation/hypokinesis; 
paradoxical septal motion; PA dilatation; and tricus-
pid regurgitation. Hemodynamic instability means
low systolic blood pressure (< 90 mmHg) and low
diastolic blood pressure (< 60 mmHg). PE diagnosis
was based on V˙/Q˙ lung scanning and computerised
tomography with contrast for all patients. The pa-
tients, after PE diagnosis, were randomly assigned
to Group 1 or 2. In each group, D-dimer levels were
measured by a different method (see below).
D-dimer measurements
We compared the D-dimer levels in cases of mas-
sive pulmonary embolism in the two groups. Group
1 included patients whose D-dimer levels were
measured with the immunoturbidimetric polyclonal
antibody method (D-dimer PLUS®), while Group 2
made use of the immunoturbidimetric monoclonal
antibody method (Innovance D-DIMER®).
D-dimer PLUS (Dade Behring, USA) is a latex-en-
hanced turbidimetric test for the quantitative deter-
mination of cross-linked fibrin degradation prod-
ucts (D-dimer) in human plasma. D-dimer measure-
ments were performed in platelet-poor citrate plas-
ma in duplicate. D-dimer PLUS assays were per-
formed and interpreted by independent operators
without knowledge of the radiographic results of
this study.
Statistics
In each group, D-dimer levels of massive and other
cases were compared. The Mann Whitney U test
SPSS 13 was used for the statistical analysis. 
In addition, we accepted significant differences as 
p < 0.05. To derive the optimal cut-off value, a re-
ceiver operator characteristic (ROC) curve was con-
structed by plotting sensitivity (true positive frac-
tion) versus 100 - specificity (false positive fraction),
and area under the curve was calculated (AUC) us-
ing MedCalc Software (Belgium).
RESULTS
The mean age of Group 1 (25F/26M) was 56.0 ±
17.9 years, and that of Group 2 (22F/16M) was 52.9
± 17.9 years. There was no statistical difference in
gender and mean age between the two groups (NS).
The patients’ hemodynamic parameters are shown
in Table I. There were significant differences be-
tween hemodynamic parameters via Mann Whitney
U test (mean heart rate, mean systolic blood pres-




















1, the mean D-dimer level of massive PE patients (n
= 7) was 1444.9 ± 657.9 µg/L and that of non-mas-
sive PE patients (n = 34) was 1304.7 ± 350.5 µg/L
(NS). In Group 2, the mean D-dimer level of mas-
sive PE patients (n = 6) was 9.7 ± 2.2 mg/L and that
of non-massive PE patients (n = 32) was 5.9 ± 1.3
mg/L (p < 0.05). The mean D-dimer levels of mas-
sive PE patients, as measured with the monoclonal
antibody method, were significantly higher com-
pared with those of non-massive patients. 
An ROC curve was made displaying sensitivity and
specificity for the immunoturbidimetric monoclon-
al antibody method (Innovance D-DIMER®) at dif-
ferent cut-off levels having an AUC of 0.802, sensi-
tivity 83.3% (95% CI: 36.1- 97.2) and specifity
78.1% (95% CI: 60.0 - 90.7). From this ROC curve,
a most appropriate cut-off value of 6.6 mg/L was
found for massive PE (ROC curve shown Figure 1).
Two patients who had non-massive PE died. The
cause of death was not related to PE. The other pa-
tients were discharged. 
DISCUSSION 
Every year, nearly 100,000-200,000 pulmonary em-
bolism cases result in death in the USA [1]. While
the mortality rates of undiagnosed patients are
around 30%, if pulmonary embolism is properly di-
agnosed in time, these mortality rates can decrease
to below 10%. Suspicion is the first step to diagnos-
ing pulmonary embolism. The clinical and physical
findings depend on the degree of vascular obstruc-
tion (the number, size and location of the embolus)
and the age of the patient and presence of coexist-
ing cardiopulmonary diseases. The clinical and lab-
oratory findings, ECG, chest X-ray and arterial
blood gas analysis are not enough to diagnose or to
exclude the diagnosis of pulmonary embolism. The
use of sequential diagnostic strategies, including D-
dimer measurement, has been shown to be useful to
rule out acute PE without further imaging testing in
a large proportion of patients. 
Within the last decade, the measurement of D-
dimer, a degradation product formed when the
cross-linked fibrin contained in a thrombus is proteo -
lyzed by plasmin, has been introduced for the pur-
pose of PE diagnosis. Various D-dimer assays are
available, including latex assays, turbidimetric im-
munoassays and enzyme-linked immunosorbent as-
says (ELISA). However, the reported D-dimer assay
sensitivities and specificities vary so widely that its
diagnostic utility has been questioned. Moreover,
due to the absence of a D-dimer reference standard,
the inter-assay correlation is poor [2]. 
A large variety of D-dimer assays are commercially
available. In general, the microplate enzyme-linked
immunosorbent assays (ELISA) and the enzyme-
linked immunofluorescent immunoassays (ELFA)
are accepted as the gold standard of the current D-
dimer assays, as they have higher sensitivities for
acute PE. Whether the other D-dimer assays (latex
quantitative, latex semi-quantitative and whole-
blood assays) have similar accuracy remains contro-
versial; however, these assays are also widely used.
Stein et al. [3] reported the superiority of the ELISA
and ELFA over all other D-dimer tests, including la-
tex quantitative assays. In contrast, a recent system-
atic review by Di Nisio et al. [4] showed that ELISA,
ELFA and latex quantitative assays have a compara-
bly higher sensitivity (from 93 to 97%), but lower
specificity (from 43 to 53%) than the latex semi-
quantitative and whole-blood D-dimer assays, re-
sulting in a more confident exclusion of acute PE at
the expense of more additional imaging testing. 
D-dimer tests have been reported to be useful pre-
dictors of both lower limb DVT and PE [5,6].
Previous studies have shown different sensitivity
and specificity percentages for numerous D-dimer
assay methods. We aimed to investigate the rela-
tionship between disease severity and D-dimer as-
TABLE I: HEMODYNAMIC PARAMETERS OF PATIENTS  
Massive pulmonary embolism Non-massive pulmonary embolism
Heart Rate (beats/min)* 108. 85 ± 3.39 95.17 ± 2.14
Systolic Blood Pressure (mmHg)** 95.00 ± 7.82 124.31 ± 2.36
Diastolic Blood Pressure (mmHg) *** 61.07 ± 6.02 77.19 ± 1.45
















FIGURE 1: ROC CURVE ANALYSIS FOR IMMUNOTURBIDIMETRIC
MONOCLONAL ANTIBODY METHOD
Area under the curve (AUC) 0.802, sensitivity 83.3% (95% CI: 36.1-
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say methods. We found that the D-dimer levels as
measured with the monoclonal antibody method
were related to the disease severity. 
The sensitivity, specificity and negative predictive
value vary depending on the type of D-dimer assay.
With the current rapid tests, both the sensitivity and
the negative predictive value are usually high (most-
ly > 95%) [7-10]. Wermeer et al., by comparing D-
dimer PLUS in combination with preclinical scores,
have provided a useful tool for clinicians to safely
exclude PE or DVT [11]. 
The combination of pretest clinical probability and
the D-dimer test can lead to a reduction of up to
50% in diagnostic imaging tests in a population
with a very low disease incidence, as in the case of
suspected PE outpatient populations [12]. Because
of the poor standardisation of D-dimer assays [13],
before inclusion into diagnostic strategies for sus-
pected PE, new D-dimer methods should be appro-
priately validated in prospective outcome studies
or, alternatively, in studies in which plasma samples
stored from outcome studies are used. 
Breen et al. reported that diagnosis based purely on
D-dimer, even in the face of supposed “low risk” is
not 100% reliable and clinical suspicion still has a
role in clinical medicine [13]. 
The most sensitive D-dimer tests are the enzyme-
linked immunosorbent (ELISA) assays. The initial
ELISA membrane plate D-dimer assays had sensitiv-
ities of over 95% [14]. ELISA D-dimer tests are
much less specific than agglutination assays, with
reported specificities varying from 20% to 50%
[14,15]. Thus, more false-positive test results would
be expected with ELISA assays, potentially resulting
in further unnecessary investigations for many pa-
tients with suspected deep vein thrombosis [16].
Our study showed that the sensitivity 83.3% and
specificity 78.1% of immunoturbidimetric mono-
clonal antibody method for D-dimer assays could
be of help. Furthermore we can propose a cut-off
level of D-dimer to differentiate the severity of pul-
monary embolism. Previous studies achieved simi-
lar results: Blamoun et al. reported a cut-off level to
distinguish mild/moderate from severe/very severe
PE at a concentration of 12.35 µg/mL, and found
that this threshold selected a higher inpatient mor-
tality and higher 60-week recurrence [17]. We did
not follow up our patients after discharge. Only two
patients died during hospital stay. We did not find
any relationship between D-dimer levels and mor-
tality rate. 
According to the RIETE Registry, patients with D-
dimer levels in the fourth quartile (≥ 4200 ng/mL-1,
latex agglutination test) had an increased risk for
overall death, fatal PE or major bleeding. We found
a similar relationship between D-dimer levels (im-
munoturbidimetric monoclonal antibody) and mas-
sive PE [18,20]. Vuilleumier et al. investigated sev-
eral different biomarkers for diagnosising non-mas-
sive PE. They reported that D-dimer level > 2000
ng/mL was a significant cut-off level for non-mas-
sive PE diagnosis [19]. 
Previous reports have found different cut-off levels
of D-dimer as a marker of disease severity or mor-
tality. These differences may be related to the use of
different D-dimer measurement methods. However,
both the sensitivity and specificity of D-dimer meas-
urements depend on the prevalence of disease in
the study population, and this explains the variety
of results in different reports [21]. 
In conclusion, we found that if the monoclonal an-
tibody method is used, patients whose D-dimer lev-
els are higher (especially higher than 6.6 mg/L)
should be considered as possibly having massive
PE. Appropriate diagnostic procedures and manage-
ment can be planned according to this finding.
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